Resveratrol and cardiovascular disease

Current Nutrition and Food Science

Volumn 4, Issue 3, 2008, Pages 227-230

  Juturu, Vijaya ^a  

^a Nutrition 21 Inc   (United States)

Author keywords

Cardioprotection; Coronary heart disease; Resveratrol

Indexed keywords

LOW DENSITY LIPOPROTEIN; RESVERATROL;

ABSENCE OF SIDE EFFECTS; ALCOHOL CONSUMPTION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG METABOLISM; DRUG STRUCTURE; ENDOTHELIUM CELL; FOOD COMPOSITION; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; RED WINE; REVIEW; RISK REDUCTION; THROMBOCYTE AGGREGATION;

VITIS VINIFERA;

EID: 55249122648     PISSN: 15734013     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340108785133374     Document Type: Review

References (25)

1. Meyer AS, Yi OS, Pearson DA, Waterhouse AL, Frankel EN. Inhibition of human low-density lipoprotein oxidation in relation to composition of phenolic antioxidants in grapes (Vitis vinifera). J Agric Food Chem 1997; 45: 1638-1643. doi: 10.1021/jf960721a10.1021/jf960721a.
2. Demrow HS, Slane BS, Folts JD. Administration of wine and grape juice inhibits in vivo platelet activity and thrombosis in stenosed canine coronary arteries. Circulation 1995; 91: 1182-88.
3. Klurfield DM, Kritchevsky D. Differential effects of alcoholic beverages on experimental atherosclerosis in rabbits. Exp Mol Pathol 1981; 34: 62-71.
4. Rimm EB, Giovannucci EL, Willett WC, et al. Prospective study of alcohol consumption and risk of coronary disease in men. Lancet 1991; 338(8765): 464-8.
5. Meng X Maliakal P. Lu H, Lee MJ, Yang CS. Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem 2004; 52(4): 935-42.
6. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004; 32(12): 1377-82.
7. Wilson T, Knight TJ, Beitz DC, Lewis DS, Engen RL. Resveratrol promotes atherosclerosis in hypercholesterolemic rabbits. Life Sci 1996; 59(1): PL15-21.
8. Wang Z, Zou J, Cao K, Hsieh TC, Huang Y, Wu JM. Dealcoholized red wine containing known amounts of resveratrol suppresses atherosclerosis in hypercholesterolemic rabbits without affecting plasma lipid levels. Int J Mol Med 2005; 16(4): 533-40.
9. Bruder JL, Hsieh T, Lerea KM. Olson SC, Wu JM. Induced cytoskeletal changes in bovine pulmonary artery endothelial cells by resveratrol and the accompanying modified responses to arterial shear stress. BMC Cell Biol 2001; 2: 1.
10. Chen WP, Su MJ, Hung LM. In vitro electrophysiological mechanisms for antiarrhythmic efficacy of resveratrol, a red wine antioxidant. Eur J Pharmacol 2007; 554(2-3): 196-204.
11. Shen M, Jia GL, Wang YM, Ma H. Cardioprotective effect of resvaratrol pretreatment on myocardial ischemia-reperfusion induced injury in rats. Vascul Pharmacol 2006; 45(2): 122-6.
12. Zou JG. Huang YZ, Chen Q, et al. Suppression of mitogenesis and regulation of cell cycle traverse by resveratrol in cultured smooth muscle cells. Int J Oncol 1999; 15: 647-651.
13. Zou JG, Huang YZ, Chen Q, Wei EH, Cao KJ, Wu JM. Effect of resveratrol on oxidative modification of human low density lipoprotein. Chin Med J 2000; 113: 99-102.
14. Stojanovic S, Sprinz H, Brede O. Efficiency and mechanism of the antioxidant action of trans-resveratrol and its analogues in the radical liposome oxidation. Arch Biochem Biophys 2001; 391(1): 79-89.
15. Brito P, Almeida LM, Dinis TC. The interaction of resveratrol with ferrylmyoglobin and peroxynitrite; protection against LDL oxidation. Free Radic Res 2002; 36(6): 621-31.
16. Wang Z, Zou J, Huang Y, Cao K, Xu Y, Wu JM. Effect of resveratrol on platelet aggregation in vivo and in vitro. Chin Med J (Engl) 2002; 115(3): 378-80.
17. Carluccio MA, Siculella L, Ancora MA, et al. Olive oil and red wine antioxidant polyphenols inhibit endothelial activation: antiatherogenic properties of Mediterranean diet phytochemicals. Arterioscler Thromb Vasc Biol 2003; 23(4): 622-9.
18. 2. Cancer Res 1999; 59: 2596-601.
19. Cruz MN, Agewall S, Schenck-Gustafsson K, Kublickiene K. Acute dilatation to phytoestrogens and estrogen receptor subtypes expression in small arteries from women with coronary heart disease. Atherosclerosis 2008; 196(1): 49-58.
20. Donnelly LE, Newton R, Kennedy GE, et al. Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. Am J Physiol Lung Cell Mol Physiol 2004; 287(4): L774-83.
21. Pinto MC, Garcia-Barrado JA, Macias P. Resveratrol is a potent inhibitor of the dioxygenase activity of lipoxygenase. J Agric Food Chem 1999; 47(12): 4842-46.
22. Wu JM, Wang ZR, Hsieh TC, Bruder JL, Zou JG. Huang YZ. Mechanism of cardioprotection by resveratrol, a phenolic anti-oxidant present in red wine (Review). Int J Mol Med 2001; 8(1): 3-17.
23. Kaur G, Roberti M, Raul F, Pendurthi UR. Suppression of human monocyte tissue factor induction by red wine phenolics and synthetic derivatives of resveratrol. Thromb Res 2007; 119(2): 247-56.
24. Lyons MM, Yu C, Toma RB, et al. Resveratrol in Raw and Baked Blueberries and Bilberries. J Agric Food Chem 2003; 51(20): 5867-70.
25. Juan ME, Vinardell MP, Planas JM. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful J Nutr 2002; 132(2): 257-60.